Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Linda A. Janisch"'
Autor:
Jason J. Luke, Steven J. Chmura, Sean P. Pitroda, Ralph R. Weichselbaum, Mark D. Hoffman, Julia Dai, Linda A. Janisch, Robyn Hseu, Hedy L. Kindler, Everett E. Vokes, Peter H. O'Donnell, Olwen M. Hahn, Blase N. Polite, Rita Nanda, Mark J. Ratain, John W. Moroney, Ami V. Desai, Chih-Yi Liao, Theodore G. Karrison, Gini F. Fleming, Corey C. Foster
Purpose:CD137 agonism and CSF1R blockade augment stereotactic body radiotherapy (SBRT) and anti-programmed death-1 in preclinical models. We evaluated the safety and efficacy of SBRT with nivolumab+urelumab (CD137 agonist) or nivolumab+cabiralizumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c6536beb4678e9cb73dd39e2e5832f0
https://doi.org/10.1158/1078-0432.c.6530619
https://doi.org/10.1158/1078-0432.c.6530619
Autor:
Jason J. Luke, Steven J. Chmura, Sean P. Pitroda, Ralph R. Weichselbaum, Mark D. Hoffman, Julia Dai, Linda A. Janisch, Robyn Hseu, Hedy L. Kindler, Everett E. Vokes, Peter H. O'Donnell, Olwen M. Hahn, Blase N. Polite, Rita Nanda, Mark J. Ratain, John W. Moroney, Ami V. Desai, Chih-Yi Liao, Theodore G. Karrison, Gini F. Fleming, Corey C. Foster
Table S1 shows the included solid tumor histologies for enrolled patients. Table S2 shows at least possibly treatment-related grade 2 or greater adverse events among patients remaining on study for at least 3 months. Table S3 shows all adverse events
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89653394de468c7c4c7a3b5bd38dc711
https://doi.org/10.1158/1078-0432.22481121
https://doi.org/10.1158/1078-0432.22481121
Autor:
Steven J. Chmura, Sean P. Pitroda, Ralph R. Weichselbaum, Thomas F. Gajewski, Gini F. Fleming, Patrick A. Ott, Joseph K. Salama, Nikolai N. Khodarev, Jyoti D. Patel, John W. Moroney, Robyn D. Hseu, Linda A. Janisch, Carlos Martinez, Lei Huang, Thomas Krausz, Tim Carll, Yuanyuan Zha, Paul Chang, Jeffrey M. Lemons, Theodore Karrison, Sandeep R. Bhave, Benjamin E. Onderdonk, Jason J. Luke
Supplemental Methods, Figures, and Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43492686dfed95d8f9f76c3197f88b2f
https://doi.org/10.1158/1078-0432.22477676
https://doi.org/10.1158/1078-0432.22477676
Autor:
Steven J. Chmura, Sean P. Pitroda, Ralph R. Weichselbaum, Thomas F. Gajewski, Gini F. Fleming, Patrick A. Ott, Joseph K. Salama, Nikolai N. Khodarev, Jyoti D. Patel, John W. Moroney, Robyn D. Hseu, Linda A. Janisch, Carlos Martinez, Lei Huang, Thomas Krausz, Tim Carll, Yuanyuan Zha, Paul Chang, Jeffrey M. Lemons, Theodore Karrison, Sandeep R. Bhave, Benjamin E. Onderdonk, Jason J. Luke
Purpose:Multisite stereotactic body radiotherapy followed by pembrolizumab (SBRT+P) has demonstrated safety in advanced solid tumors (ASTs). However, no studies have examined the relationships between irradiated tumor response, SBRT-induced tumor gen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b627cd7215f1d631ff8870943639c810
https://doi.org/10.1158/1078-0432.c.6529721.v1
https://doi.org/10.1158/1078-0432.c.6529721.v1